MA-NEURALA
24.3.2021 14:02:15 CET | Business Wire | Press release
Today, Neurala , the leader in vision AI software, announced a collaboration with FLIR Systems Inc. to deliver a full software and hardware stack AI-based industrial imaging solution. Neurala’s vision AI software unlocks the power of deep learning with no-AI-expertise-required, and now supports the creation of neural networks that can be deployed directly onto FLIR Firefly DL cameras. As a leader in machine vision cameras, FLIR Firefly DL cameras are remarkably compact with built-in inference on the edge capabilities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005235/en/
Through the collaboration, Neurala and FLIR are delivering a faster, more cost-effective entry point for customers looking to deploy deep learning on the production line. This comes at a time when manufacturers are focused on AI and automation to provide flexibility to cope with production constraints, supply chain disruptions, and scattered workforce availability.
The new solution allows customers to rapidly create deep learning models using Neurala’s Brain Builder on the VIA platform with little data and no AI expertise. These models can be directly uploaded to a FLIR Firefly DL camera using the free FLIR Spinnaker SDK. As a result, neural networks can be deployed for a wide variety of applications, including printed circuit board (PCB) inspection, detection of foreign objects, identification of surface level metal defects and product uniformity issues. With the ability to deploy directly onto the compact FLIR Firefly DL camera, an intelligent, automated inspection point can be placed practically anywhere in-line and quickly reconfigured for new applications.
“The rise of Industry 4.0 has challenged manufacturers to rethink the tools and systems they are using as part of their workflow. With cameras and sensors gathering product data and analyzing the overall health of industrial equipment, manufacturers have realized the power of AI to draw actionable insights from this data,” said Max Versace, CEO and co-founder of Neurala. “We are thrilled to collaborate with FLIR to enable customers to capitalize on the data their machines are collecting as they look to further automate their manufacturing processes.”
“Being one of the world’s first machine vision manufacturers with an inference on the edge solution, we are constantly looking for ways to help our customers stay at the cutting edge,” said Sadiq Panjwani, Vice President, Components Business, FLIR Systems. “Our collaboration with Neurala on a simplified and accessible full-stack deep learning solution is another step in that direction, bringing customers the advanced machine vision techniques required for today’s highly automated industrial environments.”
To learn more about Neurala’s Vision AI software for FLIR Firefly DL machine vision cameras, click here .
About Neurala
Neurala is a pioneer in vision AI software. On a mission to make AI more applicable and useful in real-world applications, Neurala helps industrial companies improve their quality inspection process, with technology that dramatically reduces the time, cost and skills required to build and maintain production-quality custom vision AI solutions. Founded in 2006, Neurala’s research team invented Lifelong-DNN™ (L-DNN) technology, which lowers the data requirements for AI model development and enables continuous learning in the cloud or at the edge.
Follow Neurala on Twitter (@Neurala) and on Facebook , YouTube and LinkedIn , or subscribe to our blog to receive more information about the latest developments at Neurala.
For a more in depth look at Neurala’s vision AI software, request a virtual demo .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005235/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Circularity Data: Nine Out of Ten Returned Items Lose Value for Retailers10.9.2026 13:33:00 CEST | Press release
New research finds 86% of retailers have established circularity practices, yet only 9% resell more than half of returned products at full price New research from ReBound Returns and Advanced Supply Chain (ASC) has revealed a gap between retailers’ circularity ambitions and the value they are recovering from returned products. The Circularity Index, based on research among 150 senior leaders at mid-to-large UK and European retailers, found that 86% have an established approach to circularity in returns, with practices including resale, refurbishment, repair and recycling regularly used across the business. For 27%, circularity is a core part of how returns are managed. However, translating those strategies into commercial value remains difficult. On average, 12% of returned items generate no value, while only 9% of retailers resell more than half of their returned products at full price. There is also a significant opportunity still to be captured. 82% of retailers believe that up to h
One Biosciences Receives €3,3 Million Funding Under i-Démo 5 From France 2030 to Accelerate Development of First Single-Cell Diagnostic for Triple-Negative Breast Cancer, in Collaboration With Institut Curie10.9.2026 13:02:00 CEST | Press release
One Biosciences, a techbio company spun off from Institut Curie pioneering clinical-grade single-cell tumor profiling, and Institut Curie, the leading French center for the fight against cancer, today announced support from Bpifrance through the France 2030 i-Démo1 program for the CAST project (Cancer Single-cell Analysis for Therapy), securing €3,3 Million in funding. This milestone marks a major step forward in the development of single-cell tumor profiling technology for routine cancer care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260910763012/en/ Triple-negative breast cancer (TNBC) represents approximately 15–20% of breast cancer cases. Patients face high relapse rates, rapid disease progression and limited treatment options, while clinicians still lack reliable biomarkers to predict which patients will respond to immunotherapy or chemotherapy combinations. Current diagnostic approaches average signals across mil
New WSJ Intelligence Survey Highlights the Human Skills Companies Must Protect as AI Enters the Workplace10.9.2026 13:00:00 CEST | Press release
The Cognition Index Research Report, launched in partnership with Philip Morris International, warns of “Cognitive Atrophy” and a growing AI trust gap in the workplace Philip Morris International (PMI) (NYSE: PM) and WSJ Intelligence, the in-house thought leadership consultancy for The Wall Street Journal's commercial sales organization, today unveiled The Cognition Index Research Report, a comprehensive study exploring the evolving role of human cognition in an AI-driven workplace. Surveying more than 2,500 business professionals across the United States, United Kingdom, Italy, South Africa, and Brazil, the report reveals that while business professionals are increasingly optimistic about AI’s role in improving decision-making, they continue to see human judgment, ethics, critical thinking and empathy as essential capabilities that must be actively protected and developed as AI becomes embedded in workplace workflows. “Human cognition is a bit like a muscle: use it or lose it,” says M
Compass Pathways Announces U.S. Grant Program Recipients for the Development of Post-Approval COMP360 Provider Training10.9.2026 12:35:00 CEST | Press release
Five organizations awarded grants, above the planned three, as a result of a competitive selection process with highly qualified applicants Training guidance is designed to prepare healthcare providers to deliver high-quality treatment experiences to patients receiving COMP360, if approved Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the U.S. grant program recipients to create training programs for healthcare providers (HCPs) that will be involved in the delivery of psychedelic treatments, such as COMP360 psilocybin. These programs are intended to address both the need for foundational training in psychedelics, as well as ensuring HCPs are well-prepared to care for patients receiving treatment with COMP360 following its expected commercial launch, if approved. The recipients were selected through a competitive application process based on their expertise and proven abilit
Compass Pathways to Participate in Investor Conferences the Week of September 14th10.9.2026 12:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will participate in the following investor conferences the week of September 14th: H.C. Wainwright Annual Global Investment Conference – New York, NY: Fireside chat at 3:30pm ET on September 15, 2026 Morgan Stanley 24th Annual Global Healthcare Conference – New York, NY: Fireside chat at 11:30am ET on September 16, 2026 Deutsche Bank’s 2026 Healthcare Summit – New York, NY: Fireside chat at 11:00am ET on September 17, 2026 A live audio webcast of the fireside chats will be accessible from the “Events” page of the Investors section of the Compass website. A replay of the webcast will be accessible for 30 days following each event. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlockin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
